McKesson (NYSE:MCK) had its price target lifted by analysts at Mizuho from $140.00 to $147.00 in a report released on Thursday, The Fly reports. The brokerage currently has a “neutral” rating on the stock. Mizuho’s price objective suggests a potential downside of 1.62% from the stock’s previous close.
Other equities research analysts have also recently issued research reports about the company. Guggenheim upgraded McKesson from a “neutral” rating to a “buy” rating in a research note on Friday, March 13th. Credit Suisse Group began coverage on McKesson in a report on Wednesday, April 22nd. They issued a “neutral” rating and a $146.00 target price on the stock. Cfra dropped their target price on McKesson from $179.00 to $171.00 and set a “buy” rating on the stock in a report on Wednesday. Morgan Stanley dropped their target price on McKesson from $182.00 to $150.00 and set an “overweight” rating on the stock in a report on Friday, March 27th. Finally, ValuEngine lowered McKesson from a “sell” rating to a “strong sell” rating in a report on Friday, May 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $168.50.
NYSE MCK traded up $3.60 on Thursday, reaching $149.42. The stock had a trading volume of 902,930 shares, compared to its average volume of 1,730,228. The company has a debt-to-equity ratio of 1.51, a quick ratio of 0.56 and a current ratio of 0.99. McKesson has a 12-month low of $112.60 and a 12-month high of $172.18. The business’s 50-day moving average price is $136.14 and its 200 day moving average price is $142.81. The stock has a market cap of $25.80 billion, a P/E ratio of 29.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.82.
In related news, CEO Brian S. Tyler sold 4,063 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $135.00, for a total transaction of $548,505.00. Following the transaction, the chief executive officer now owns 16,255 shares of the company’s stock, valued at $2,194,425. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 8,187 shares of company stock worth $1,064,057 in the last ninety days. 0.88% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in MCK. Reilly Financial Advisors LLC boosted its position in McKesson by 198.5% during the first quarter. Reilly Financial Advisors LLC now owns 200 shares of the company’s stock worth $27,000 after purchasing an additional 133 shares in the last quarter. Trust Co. of Vermont boosted its position in McKesson by 254.2% during the first quarter. Trust Co. of Vermont now owns 209 shares of the company’s stock worth $28,000 after purchasing an additional 150 shares in the last quarter. Keebeck Wealth Management LLC purchased a new stake in McKesson during the fourth quarter worth $29,000. Penserra Capital Management LLC boosted its position in McKesson by 55.6% during the fourth quarter. Penserra Capital Management LLC now owns 210 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares in the last quarter. Finally, Fred Alger Management LLC purchased a new stake in McKesson during the fourth quarter worth $32,000. 84.96% of the stock is currently owned by hedge funds and other institutional investors.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
See Also: FinTech
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.